Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bamosiran
- Development stage
- Phase 2
- Lead developer
- Sylentis
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Topical, Ophthalmic
01
Overview
Bamosiran is an investigational oligonucleotide pharmaceutical classified as a small interfering RNA (siRNA) therapy. It is designed to lower intraocular pressure by selectively inhibiting the expression of β2-adrenergic receptors in ocular tissues via RNA interference. This mechanism reduces aqueous humour production, which is directly involved in the regulation of intraocular pressure. Bamosiran has been developed primarily for the treatment of glaucoma and ocular hypertension and has completed Phase 2 clinical trials demonstrating efficacy and good tolerability as a topical eye drop formulation[1][2][3][4][5][6].
- Other names
- bamosiran
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on bamosiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bamosiran.